Cargando…

P357 Update on risk factors for Candida krusei-Fungemia

POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Institut für Medizinische Mikrobiologie der Universitätsmedizin Essen, Robert Koch Haus, Virchow Straße 179, 45147 Essen, Germany OBJECTIVES: Infection with Candida species have been an increasing threat to hospital patients worldwide. During...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Julia C., Verhasselt, Hedda Luise, Rath, Peter Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509884/
http://dx.doi.org/10.1093/mmy/myac072.P357
_version_ 1784797327692660736
author Jansen, Julia C.
Verhasselt, Hedda Luise
Rath, Peter Michael
author_facet Jansen, Julia C.
Verhasselt, Hedda Luise
Rath, Peter Michael
author_sort Jansen, Julia C.
collection PubMed
description POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Institut für Medizinische Mikrobiologie der Universitätsmedizin Essen, Robert Koch Haus, Virchow Straße 179, 45147 Essen, Germany OBJECTIVES: Infection with Candida species have been an increasing threat to hospital patients worldwide. During the last decade research has shown high mortality rates associated with candidemia and progressing drug resistance to NAC (non-albicans Candida) species. This study aims to solidify risk factors for C. krusei fungemia. PATIENTS AND METHODS: We retrospectively analyzed patient data with at least one C. krusei or C. albicans positive blood culture at Essen University Hospital between 2008–2020. Relevant categories consisted of age, gender, underlying condition, central venous catheters (CVC), steroids, leukopenia <4000/μl, diabetes, antifungal treatment, hospital ward, and outcome. We used the Chi-Squared test to compare categorical valuables. P-values were considered significant <.05 and highly significant <.01. RESULTS: From 1380 patients who tested positive for Candida spp. between 2008–2020, 40 were positive for C. krusei and 786 for C. albicans. Candida albicans presented as the leading species (57.0%), followed by C. glabrata (23.5%), C. parapsilosis (5.8%), C. tropicals (5.1%), and C. krusei (2.9%). A total of 67.6% of patients were located at ICU. Incidence rates for Candida positive blood cultures increased from 1.0% to 10.0%. Candida krusei was most common in patients 51–60 years of age. In both groups, overall survival was identical (52.2% C. krusei/54.3% C. albicans). For C. krusei correlation between outcome and antifungal treatment was highly significant (P .044). A total of 20% more C. krusei infected hemato-oncology patients died than in the C. albicans group (62.5% C. krusei/46.5% C. albicans). In all, 60.0% of C. krusei patients on ICU died. In the C. krusei group all patients with CVC died and all patients without survived. CONCLUSION: Candida-positive blood cultures increased from 1% in 2008 to 10% in 2020. Three major risk factors for C. krusei fungemia were found: CVC, hemato-oncology malignancies, and leukocytopenia.
format Online
Article
Text
id pubmed-9509884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95098842022-09-26 P357 Update on risk factors for Candida krusei-Fungemia Jansen, Julia C. Verhasselt, Hedda Luise Rath, Peter Michael Med Mycol Oral Presentations POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: Institut für Medizinische Mikrobiologie der Universitätsmedizin Essen, Robert Koch Haus, Virchow Straße 179, 45147 Essen, Germany OBJECTIVES: Infection with Candida species have been an increasing threat to hospital patients worldwide. During the last decade research has shown high mortality rates associated with candidemia and progressing drug resistance to NAC (non-albicans Candida) species. This study aims to solidify risk factors for C. krusei fungemia. PATIENTS AND METHODS: We retrospectively analyzed patient data with at least one C. krusei or C. albicans positive blood culture at Essen University Hospital between 2008–2020. Relevant categories consisted of age, gender, underlying condition, central venous catheters (CVC), steroids, leukopenia <4000/μl, diabetes, antifungal treatment, hospital ward, and outcome. We used the Chi-Squared test to compare categorical valuables. P-values were considered significant <.05 and highly significant <.01. RESULTS: From 1380 patients who tested positive for Candida spp. between 2008–2020, 40 were positive for C. krusei and 786 for C. albicans. Candida albicans presented as the leading species (57.0%), followed by C. glabrata (23.5%), C. parapsilosis (5.8%), C. tropicals (5.1%), and C. krusei (2.9%). A total of 67.6% of patients were located at ICU. Incidence rates for Candida positive blood cultures increased from 1.0% to 10.0%. Candida krusei was most common in patients 51–60 years of age. In both groups, overall survival was identical (52.2% C. krusei/54.3% C. albicans). For C. krusei correlation between outcome and antifungal treatment was highly significant (P .044). A total of 20% more C. krusei infected hemato-oncology patients died than in the C. albicans group (62.5% C. krusei/46.5% C. albicans). In all, 60.0% of C. krusei patients on ICU died. In the C. krusei group all patients with CVC died and all patients without survived. CONCLUSION: Candida-positive blood cultures increased from 1% in 2008 to 10% in 2020. Three major risk factors for C. krusei fungemia were found: CVC, hemato-oncology malignancies, and leukocytopenia. Oxford University Press 2022-09-20 /pmc/articles/PMC9509884/ http://dx.doi.org/10.1093/mmy/myac072.P357 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Jansen, Julia C.
Verhasselt, Hedda Luise
Rath, Peter Michael
P357 Update on risk factors for Candida krusei-Fungemia
title P357 Update on risk factors for Candida krusei-Fungemia
title_full P357 Update on risk factors for Candida krusei-Fungemia
title_fullStr P357 Update on risk factors for Candida krusei-Fungemia
title_full_unstemmed P357 Update on risk factors for Candida krusei-Fungemia
title_short P357 Update on risk factors for Candida krusei-Fungemia
title_sort p357 update on risk factors for candida krusei-fungemia
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509884/
http://dx.doi.org/10.1093/mmy/myac072.P357
work_keys_str_mv AT jansenjuliac p357updateonriskfactorsforcandidakruseifungemia
AT verhasseltheddaluise p357updateonriskfactorsforcandidakruseifungemia
AT rathpetermichael p357updateonriskfactorsforcandidakruseifungemia